

REGISTERED CHARITY NUMBER: 0276829

**REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022
FOR
BRITISH ASSOCIATION FOR CYTOPATHOLOGY**

Ellis Atkins
Chartered Accountants
The Atrium Business Centre
Curtis Road
Dorking
Surrey
RH4 1XA

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2022**

	Page
Report of the Trustees	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10 to 15
Detailed Statement of Financial Activities	16

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2022

The trustees present their report with the financial statements of the charity for the year ended 31 March 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The British Association of Cytopathology (BAC), which is registered as a charity, was founded in 2011 resulting from the merger of British Society for Clinical Cytology (BSCC) and the National Association of Cytologists (NAC). The BAC exists to advance the science and art of Cytopathology by encouraging higher standards in Cytopathology for the benefit of the public and to encourage research in Cytopathology and related fields for the publication of useful results. In pursuit of these aims and objectives, the BAC has the power to receive contributions via a membership fee and raise funds where appropriate, to finance the work of the BAC.

To achieve these aims and objectives, the BAC will hold regular Scientific Meetings, educational study days, training courses and workshops and will facilitate a Continuous Education Certificate scheme open to all members. The BAC will work with groups of a similar nature and exchange information, advice and knowledge with them, including cooperation with other professional bodies, charities, statutory and non-statutory organisations.

Significant activities

All the members receive the official journal "Cytopathology" as well as the regular magazine "SCAN". "SCAN" is now published online and will be incorporated into "Cytopathology" going forward. The aim of Cytopathology is to publish articles relating to those aspects of cytology which will increase our knowledge and understanding of the aetiology, diagnosis and management of human disease. It contains original articles and critical reviews on all aspects of clinical cytology in its broadest sense: including gynaecological and non-gynaecological cytology, fine needle aspiration and screening strategy. The journal welcomes papers on ultrastructural, histochemical and immunocytochemical studies of the cell as well as articles on quantitative cytology and DNA hybridization.

The aim of Cytopath Editorial policy reflects the interest of cytopathologists and cytotechnologists alike as well as the interest of clinicians using the cytology service. It also reflects the interest of biological scientists whose work involves research of the cellular level. We continue to correlate information on matters cytological including progress of the NHS Cervical Screening Programme.

All members receive the journal

Public benefit

The trustees confirm that they have referred to the guidance contained in the Charity Commissioner's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities.

The trustees are satisfied that the charity continues to meet the required public benefit test through its objectives and activities described above.

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2022

ACHIEVEMENT AND PERFORMANCE

Charitable activities

www.britishcytology.org.uk

The website continues to develop and covers the evolution of the BAC, meetings and news/research within the field of Cytopathology. The BAC is keen to develop an educational section using cases/modules for self learning. We encourage any comments or ideas for developing the website and are particularly interested to hear if you have any material that would provide a valuable resource to our members. There are plans to review the website to create a more friendly user interface and use more images.

Continuing Education Scheme

Since the merger of the BSCC and NAC, the Continuing Education Scheme developed by the NAC has been adopted as part of the BAC. It provides a means of recording on-going educational activities carried out by cytology screeners and biomedical scientists. Members of the scheme submit evidence to gain a certificate of achievement after attainment of a specified number of credits within a defined time frame.

BAC have worked hard to establish ourselves as a professional body for cytopathology in the UK, and it has taken some time, but through working closely with other relevant organizations, national bodies, government departments we are now the 'go-to' body which represents cytology in all its forms within the UK, recognized and respected across the world.

Due to COVID-19 restrictions, the BAC has continued its educational meetings in the form of Webinars hosted through Zoom. These have been very well-received and have attracted many attendees not only from the UK but overseas too. The Webinars have been recorded and can be found on 'YouTube'.

The BAC Twitter account is being widely used and the number of followers has increased greatly over the year.

FINANCIAL REVIEW

Financial position

The Association has generated a surplus in the year of £5,610 (2021: £12,757 surplus) from its activities throughout the year.

The revised arrangements for our journal Cytopathology continue to generate increased royalty payments from the publishers Wiley. However, the surpluses realised from Conferences and meetings in recent years are now of much increased importance to the finances of the BAC. No conference was held in this financial year.

At the year end, the BAC still has available reserves in excess of £400,000 which we consider to be in line with the reserves policy referred to below.

Executive is satisfied with the results shown, which are very much in line with expectations.

Investment policy and objectives

The Constitution of the BAC authorises the Executive to make and hold investments using the funds of the charity.

Cash balances are currently held with Lloyds Bank and The National Savings Bank. In addition, the BAC holds certain investments in quoted securities, which have been previously donated to it.

Executive, having regard to the liquidity requirements of the organisation have operated a policy of keeping available funds within interest bearing deposit accounts.

Reserves policy

The BAC maintains reserves to enable us to provide an uninterrupted service to our members. It is considered that reserves should be able to support a minimum of one year, and ideally up to two years operating costs. The BAC now has total reserves of £420,341 (2021: £414,731), and this is within the range of our reserves policy.

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2022

FUTURE PLANS

Towards the end of last year's Chair's report, I encouraged members to vote in the then upcoming ballot for three vacancies on the BAC Exec. As a result, I am delighted to welcome new members of the Executive: Mrs Kirstie Rice, Dr Bijal Shah and Dr Martina Munonyara. They have already got their feet under the table (at least virtually!) and their commitment enables the Executive to continue its work of governing and developing your Association. There are no vacancies this year but many posts are due for re-election in 2023 so please consider supporting the BAC next year by standing for the Executive.

Although the world has been slowly emerging from the effects of the Covid19 pandemic and our response to it, there is not a sense of "business-as usual". The slow transition from pandemic to endemic means there is still a degree of uncertainty, particularly as regards scheduled "in-person" academic meetings.

Thankfully, the BAC were able to hold a very successful hybrid meeting to celebrate our 10th anniversary on 15th October 2021. 48 delegates were able to attend the DoubleTree Hotel in Nottingham with a further 41 viewing online. We heard from Philippe Viehl, the Editor-in-Chief of Cytopathology, and Hedley Glencross regarding the new "Scan" section of the journal, an update from Alison Cropper, BAC President, about the new Gynae Code of Practice for UK Cervical Screening and excellent talks from Robbie Wilson on Molecular Diagnostics and Mina Desai on HPV testing globally, focussing on India and a campaign to offer testing outside major population centres. There were also four excellent case presentations (one in person, three online) with the Brighton Award for the best being won by Kris Leung from Cornwall. Most of these are available (for members only) on the BAC website.

The day was rounded off by a presentation from Paul Cross (with support from Kay Ellis and Allan Wilson) looking back on the first 10 years of the BAC. It was a reminder of how far we have come and what changes have taken place. Throughout all this time, the BAC has worked to promote professional standards in all uses of cytology and to understand and communicate the consequences of any changes to our members while seeking to provide guidance for those affected.

There followed a very enjoyable dinner in the evening attended by most "in-person" delegates. David Wells, CEO of the IBMS, gave a short but incisive speech which recognised the BAC's integrated structure, with both biomedical scientists and medical practitioners having major roles and generating guidance and policies reflective of that approach.

The next significant in-person event was due to be a joint meeting with the International Academy of Cytology (IAC) in December 2021. However, as the autumn wore on and the Omicron coronavirus variant blossomed, it became apparent that attendance was likely to be severely compromised and the tutorial was eventually held as a purely online event on July 18th and 19th 2022. Over 200 delegates, mainly from Europe, Africa and Asia (for "time zone" reasons) were treated to an excellent program spanning diagnostic and cervical cytopathology with an overarching theme involving approaches to small specimens, both "cytological" and "histological". The sessions were excellently moderated by Zubair Baloch (Pennsylvania) and our own Ashish Chandra.

Two further BAC webinars were held in the last year. Dr Chiara Herzog spoke about "Harnessing the epigenetic footprint of cervical samples for breast and ovarian cancer detection and prediction" and Dr Angela Ralte discussed "Intraoperative cytology of the female genital tract: an alternative to frozen sections". These were free to attend and recordings are available via the BAC website. In addition, the BAC completed its short series of webinars for the Royal College of Radiologists, primarily based around techniques for fine needle aspiration of head and neck lesions and Rapid Onsite Evaluation (ROSE). We hope to build on this in the coming year in association with partner organisations such as the IBMS, Royal College of Pathologists and Royal College of Radiologists. Regarding webinars, we are happy to facilitate short sessions from departments presenting interesting cases - anything from 30 minutes to up to two hours. Please get in touch if you have an idea for such a session. Our email address is mail@britishcytology.org.uk

Finally (in terms of looking back), we held a member's survey and the message that came out loud and clear was that the single most important thing for BAC members was access to high quality training and educational material - which brings me to the future.

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2022

Firstly, as I mentioned in the summary of last year's Annual Scientific Meeting, there is a new section in Cytopathology called "Scan" both as a continuation of the title of the BAC's inhouse magazine and also "Serving Cytology Across Nations". This aims to provide articles with a technical focus that go beyond the textbooks and are designed to give the feeling of standing next to someone in the clinic or laboratory - the "finer detail of cytology" as the editors put it. The September issue of Cytopathology includes an introduction to the Scan section from Ashish Chandra and Hedley Glencross. There follows an excellent article from Hedley on the "finer details" of cytocentrifugation. Again, contributions and suggestions are welcomed from BAC members and wider afield.

Secondly, over the next few months, the BAC will be developing a new website provided by web designers Moresoda in collaboration with the BAC Media Group. This will have the advantages of being easier to manage and will also be able to more easily process membership details and any potential payments. In addition, it is a welcome opportunity to revamp and expand the educational resources that are on the site. We are early in the planning stages of this and are always interested in suggestions for (and offers of) content. Feel free to email. We are very excited about the new website and will be updating members over the next few months as it develops.

The 2022 AGM and Annual Scientific Meeting took place in December 2022. We had hoped that this would be an in-person event with a workshop but we were thwarted this time, not by Covid-19, but by rail strikes in the UK on the day of the meeting, meaning that attendance would be impossible for most and difficult for the rest. We took the decision to move to an online meeting only with over 200 delegates attending.

Lastly, our Treasurer, Kay Ellis, hands the role over to Kirstie Rice at the AGM. I'd like to take the opportunity to warmly thank Kay for her many (at least 23!) years of hard work in this role for the BAC and its precursor organisations, the NAC and BSCC. She has provided absolutely rock-solid support in the role for the BAC and the much-needed reassurance of continuity in the transition from those organisations to the BAC as well as being an excellent "reality-checker" at all times. Many thanks again and we wish Kirstie all the best in her new role.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The British Association for Cytopathology (BAC) was formed in 2011 following the merger of the British Society for Clinical Cytology (BSCC) and the National Association of Cytologists (NAC). BAC is a registered charity, charity number 276829, duly constituted under a Deed of Trust. The constitution and Rules were adopted on 25th September 1978, amended on 12th September 1982, 19th September 1990, 18th September 1991, 15th September 1998, 12th September 2006, 15th July 2011 and 15th September 2012.

Appointment to Executive

Executive members are appointed for a period of three years, and are appointed by a majority vote from nominations received at the Annual Meeting. The Officers of the BAC are selected from the Executive.

The AGM of 4th November 2017 approved some changes to The BAC Constitution, which are available on the BAC website. The major change was the expansion of the Executive to 12 elected members plus the President.

For the purposes of the Charities Act the officers and members of the BAC effectively act as the Charitable Trustees.

Organisation

The charity is based within the UK. It no longer has any permanent office accommodation of its own but its administration is handled through IBMS in London. The academic work of the organisation is controlled and organised through a series of committees, the membership of which is shown below.

We now have a "front desk" manned throughout the full working week through arrangements with IBMS in London. The remaining administrative duties have been devolved to members of The Executive.

Induction and training of new members

New members of the Executive are briefed on their legal obligations under charity law, the committee, and decision making processes of the Organisation.

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 MARCH 2022

STRUCTURE, GOVERNANCE AND MANAGEMENT

Risk management

The Executive is responsible for safeguarding the assets of the BAC and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reasonable assurance that:

- a) the BAC is operating efficiently and effectively;
- b) its assets are safeguarded against unauthorised use or disposition;
- c) proper records are maintained and are reliable;
- d) the BAC complies with relevant laws and regulations

The systems of internal control are designed to provide reasonable, but not absolute, assurance against material misstatement or loss. They include:

- e) regular meetings and reviews conducted by the Executive
- f) regular consideration by the Executive of the financial results in light of known expectations, non-financial performance indicators and review;
- g) delegation of authority and segregation of duties;
- h) identification and management of risks.

The Executive actively review the main risk which the charity faces on a regular basis, and believe that maintaining our free reserves at the levels stated below, combined with our annual review of the controls over key financial systems carried out through various reviews, will provide sufficient resources in the event of adverse conditions. The Executive have also examined other operational and business risks which we face, and confirm that they have established systems to mitigate the significant risks. The Executive wish to ensure that the BAC's internal financial controls in particular, conform to guidelines issued by the Charity Commission.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

0276829

Principal address

12 Coldbath Square
London
EC1R 5HL

Trustees

Prof A Wilson

Mrs K Ellis

Mrs S Mehew

Mrs A Cropper

Dr A Maddox

L Wheeldon

Dr M Munonyara (appointed 15/10/2021)

K Rice (appointed 15/10/2021)

Independent Examiner

Philip Longstaff FCA

ICAEW

Ellis Atkins

Chartered Accountants

The Atrium Business Centre

Curtis Road

Dorking

Surrey

RH4 1XA

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 MARCH 2022

REFERENCE AND ADMINISTRATIVE DETAILS

Executive Members

Dr Louise Smart

Dr Ash Chandra

Mrs Helen Burrell

Ms Alison Malkin

Dr Bijal Shah

Co-opted Members

Professor Philippe Viehl

Mr Hedley Glencross

Approved by order of the board of trustees on17/1/2023..... and signed on its behalf by: "

.....
Mrs A Cropper - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
BRITISH ASSOCIATION FOR CYTOPATHOLOGY**

Independent examiner's report to the trustees of British Association for Cytopathology

I report to the charity trustees on my examination of the accounts of British Association for Cytopathology (the Trust) for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Philip Longstaff FCA
ICAEW
Ellis Atkins
Chartered Accountants
The Atrium Business Centre
Curtis Road
Dorking
Surrey
RH4 1XA

Date:

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

**STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022**

	Notes	Unrestricted fund £	Restricted fund £	31/3/22 Total funds £	31/3/21 Total funds £
INCOME AND ENDOWMENTS FROM:					
Donations and legacies		50	13,333	13,383	-
Charitable activities	3				
Advancement of scientific research		58,539	-	58,539	56,946
Investment income	2	5	-	5	348
Total		<u>58,594</u>	<u>13,333</u>	<u>71,927</u>	<u>57,294</u>
EXPENDITURE ON					
Charitable activities	4				
Advancement of scientific research		71,911	-	71,911	52,289
Net gains on investments		5,594	-	5,594	7,752
NET INCOME/(EXPENDITURE)		<u>(7,723)</u>	<u>13,333</u>	<u>5,610</u>	<u>12,757</u>
RECONCILIATION OF FUNDS					
Total funds brought forward		414,731	-	414,731	401,974
TOTAL FUNDS CARRIED FORWARD		<u><u>407,008</u></u>	<u><u>13,333</u></u>	<u><u>420,341</u></u>	<u><u>414,731</u></u>

The notes form part of these financial statements

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

**BALANCE SHEET
31 MARCH 2022**

	Notes	Unrestricted fund £	Restricted fund £	31/3/22 Total funds £	31/3/21 Total funds £
FIXED ASSETS					
Tangible assets	8	635	-	635	847
Investments	9	36,901	-	36,901	31,307
		<u>37,536</u>	<u>-</u>	<u>37,536</u>	<u>32,154</u>
CURRENT ASSETS					
Debtors	10	9,237	-	9,237	9,028
Cash at bank		376,835	13,333	390,168	393,667
		<u>386,072</u>	<u>13,333</u>	<u>399,405</u>	<u>402,695</u>
CREDITORS					
Amounts falling due within one year	11	(16,600)	-	(16,600)	(20,118)
NET CURRENT ASSETS		<u>369,472</u>	<u>13,333</u>	<u>382,805</u>	<u>382,577</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>407,008</u>	<u>13,333</u>	<u>420,341</u>	<u>414,731</u>
NET ASSETS		<u>407,008</u>	<u>13,333</u>	<u>420,341</u>	<u>414,731</u>
FUNDS	12				
Unrestricted funds				407,008	414,731
Restricted funds				13,333	-
TOTAL FUNDS				<u>420,341</u>	<u>414,731</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 17/1/2023 and were signed on its behalf by:



A Cropper - Trustee



K Rice - Trustee

The notes form part of these financial statements

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2022

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The financial statements present information about the charity as an individual undertaking and not as a group.

There are no material uncertainties regarding the charity's ability to continue as a going concern.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Allocation and apportionment of costs

The charity allocates its support costs on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Website development	- 33% on cost
Plant and machinery	- 25% on cost
Computer equipment	- 33% on cost

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

BRITISH ASSOCIATION FOR CYTOPATHOLOGY
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022

2. INVESTMENT INCOME		31/3/22	31/3/21
		£	£
Deposit account interest		<u>5</u>	<u>348</u>
3. INCOME FROM CHARITABLE ACTIVITIES		31/3/22	31/3/21
		£	£
Subscriptions	Activity	<u>21,382</u>	<u>22,401</u>
Journal royalties	Advancement of scientific research	<u>37,157</u>	<u>34,545</u>
	Advancement of scientific research	<u>58,539</u>	<u>56,946</u>
4. CHARITABLE ACTIVITIES COSTS			
	Direct Costs	Support costs (see note 5)	Totals
	£	£	£
Advancement of scientific research	<u>37,353</u>	<u>34,558</u>	<u>71,911</u>
5. SUPPORT COSTS			
	Management	Governance costs	Totals
	£	£	£
Advancement of scientific research	<u>31,618</u>	<u>2,940</u>	<u>34,558</u>
Support costs, included in the above, are as follows:			
		31/3/22	31/3/21
		Advancement of scientific research	Total activities
		£	£
Office costs		<u>5,072</u>	<u>3,191</u>
Travel		<u>1,697</u>	<u>1,672</u>
Administration costs		<u>24,120</u>	<u>24,000</u>
Subscriptions		<u>384</u>	<u>384</u>
Depreciation of tangible assets		<u>212</u>	<u>282</u>
Interest payable and similar charges		<u>133</u>	<u>178</u>
Independent Examiner's Fee		<u>2,940</u>	<u>2,940</u>
		<u>34,558</u>	<u>32,647</u>

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022**

6. INDEPENDENT EXAMINER'S REMUNERATION

	31/3/22	31/3/21
	£	£
Independent Examiner's Fee	<u>2,940</u>	<u>2,940</u>

Independent examiners remuneration for the year was £2,940 (2021: £2,940).

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2022 nor for the year ended 31 March 2021.

Trustees' expenses

Details relating to trustees' expenses are given below.

Executive members

Travelling and directly incurred other expenses amounting to £953 were reimbursed to 2 Executive Members (2021 - £5,757 to 11 Executive Members). This includes £953 reimbursed to 2 trustees (2021: £4,374 to 6 trustees).

There were no staff directly employed during the year or previous period.

8. TANGIBLE FIXED ASSETS

	Website development £	Plant and machinery £	Computer equipment £	Totals £
COST				
At 1 April 2021 and 31 March 2022	<u>17,626</u>	<u>6,339</u>	<u>524</u>	<u>24,489</u>
DEPRECIATION				
At 1 April 2021	17,626	5,492	524	23,642
Charge for year	-	212	-	212
At 31 March 2022	<u>17,626</u>	<u>5,704</u>	<u>524</u>	<u>23,854</u>
NET BOOK VALUE				
At 31 March 2022	<u>-</u>	<u>635</u>	<u>-</u>	<u>635</u>
At 31 March 2021	<u>-</u>	<u>847</u>	<u>-</u>	<u>847</u>

BRITISH ASSOCIATION FOR CYTOPATHOLOGY
NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022

9. FIXED ASSET INVESTMENTS

	Listed investments £
MARKET VALUE	
At 1 April 2021	31,307
Revaluations	<u>5,594</u>
At 31 March 2022	<u>36,901</u>
NET BOOK VALUE	
At 31 March 2022	<u>36,901</u>
At 31 March 2021	<u>31,307</u>

There were no investment assets outside the UK.

Cost or valuation at 31 March 2022 is represented by:

	Listed investments £
Valuation in 2022	<u>36,901</u>

The market value is represented by the quoted market price at 31st March 2022.

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31/3/22 £	31/3/21 £
Accrued royalty income	<u>9,237</u>	<u>9,028</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31/3/22 £	31/3/21 £
Accruals and deferred income	6,526	9,510
Prepaid subscriptions	<u>10,074</u>	<u>10,608</u>
	<u>16,600</u>	<u>20,118</u>

12. MOVEMENT IN FUNDS

	At 1.4.21 £	Net movement in funds £	At 31.3.22 £
Unrestricted funds			
General fund	414,731	(7,723)	407,008
Restricted funds			
Mina Desai Award		13,333	13,333
TOTAL FUNDS	<u>414,731</u>	<u>5,610</u>	<u>420,341</u>

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2022**

12. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	58,594	(71,911)	5,594	(7,723)
Restricted funds				
Mina Desai Award	13,333	-	-	13,333
TOTAL FUNDS	<u>71,927</u>	<u>(71,911)</u>	<u>5,594</u>	<u>5,610</u>

Comparatives for movement in funds

	At 1.4.20 £	Net movement in funds £	At 31.3.21 £
Unrestricted funds			
General fund	401,974	12,757	414,731
TOTAL FUNDS	<u>401,974</u>	<u>12,757</u>	<u>414,731</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	57,294	(52,289)	7,752	12,757
TOTAL FUNDS	<u>57,294</u>	<u>(52,289)</u>	<u>7,752</u>	<u>12,757</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.4.20 £	Net movement in funds £	At 31.3.22 £
Unrestricted funds			
General fund	401,974	5,034	407,008
Restricted funds, Mina Desai Award	-	13,333	13,333
TOTAL FUNDS	<u>401,974</u>	<u>18,367</u>	<u>420,341</u>

BRITISH ASSOCIATION FOR CYTOPATHOLOGY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2022

12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds:				
General fund	115,888	(124,200)	13,346	5,034
Restricted funds:				
Mina Desai Award	13,333	-	-	13,333
TOTAL FUNDS	<u>129,221</u>	<u>(124,200)</u>	<u>13,346</u>	<u>18,367</u>

The Association operates unrestricted and restricted funds. Unrestricted funds are used for the general and scientific activities of BAC.

The Association recognised a donation received in the year of £ 13,333 as a restricted fund (2021: Nil). This donation is specifically to cover costs relating to the annual Mina Desai Award, an annual bursary for the European Conference and a tri-annual bursary for the International meeting. The donation is expected to fund this expenditure for up to ten years.

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2022.

BRITISH ASSOCIATION FOR CYTOPATHOLOGY
DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2022

	31/3/22 £	31/3/21 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	13,383	-
Investment income		
Deposit account interest	5	348
Charitable activities		
Subscriptions	21,382	22,401
Journal royalties	37,157	34,545
	<u>58,539</u>	<u>56,946</u>
Total incoming resources	71,927	57,294
EXPENDITURE		
Charitable activities		
Advertising and website	3,426	4,164
Journal costs	14,299	13,827
Tutorial and ASM costs	19,628	1,651
	<u>37,353</u>	<u>19,642</u>
Support costs		
Management		
Office costs	5,072	3,191
Travel	1,697	1,672
Administration costs	24,120	24,000
Subscriptions	384	384
Depreciation of tangible assets	212	282
Bank charges	133	178
	<u>31,618</u>	<u>29,707</u>
Governance costs		
Independent Examiner's Fee	2,940	2,940
Total resources expended	71,911	52,289
Net income	<u><u>16</u></u>	<u><u>5,005</u></u>

This page does not form part of the statutory financial statements